Clinical practice guidelines for diagnosis and treatment of chronic lymphocytic leukemia (CLL) in the Netherlands

Publication date: Available online 25 September 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): S. Kersting, S.I.M. Neppelenbroek, H.P.J. Visser, M v Gelder, M.D. Levin, R. Mous, E.F.M. Posthuma, H.M. van der Straaten, A.P. Kater In recent years, considerable progress has been made in treatment of patients with chronic lymphocytic leukaemia (CLL) and new potent drugs have become available. Therefore, the CLL working party of the Dutch/ Belgium Haemato-Oncology Foundation for Adults in the Netherlands (HOVON) framework revised the Dutch guidelines based on new studies and expert opinion of members of the working group. Not only efficacy, but also quality of life and socio-economic impact were taken into account in the formulation of the recommendations. This has led to guidelines that still favor chemo-immunotherapy in the majority of CLL patients and conserve kinase-inhibitors for selected patients only.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research